Sharen schreef op 31 maart 2022 10:03:
[...]
Allereerst bedankt voor je AB, wordt gewaardeerd.
Maar hoezo was dat een “verkeerde suggestie” waarmee ik “beleggers valse hoop geef “ ?
Zie hieronder het transscript van de analisten call van 17 maart waaruit geconcludeerd mag worden dat Pharming aan de slag gaat met minimaal één extra indicatie van Leniolisib, en mogelijk meer.
seekingalpha.com/article/4496298-phar...*
Ten aanzien van ‘minimaal één’ :
Tijdens de Q@A, na een vraag van Joe Pantginis:“Novartis is a very solid company, and they have done some very solid research collaborations on leniolisib and additional indications with renowned institutions.
And that's actually something we're looking into as well, to actually see whether we can actually formulate an additional clinical trial program in the not too distant future to investigate a subsequent indication for leniolisib beyond APDS”
Tijdens de Q&A, tijdens een vraag van Alex Cogut:“But also, as I was just saying earlier, in actually trying to formulate these research collaborations that Novartis has done for leniolisib and coming to hopefully filing another IND in the not too distant future for leniolisib for a secondary indication”
*
Ten aanzien van ‘mogelijk meer’ :
Tijdens de Q&A, tijdens een vraag van Alex Cogut:“No, because there's several research collaborations that Novartis have engaged in. And we're very happy to have Chief Scientific Officer since last year, August, he's diving into these things in a very enthusiastic way. And we're trying to, of course, to make a selection, which of these research collaborations research results are the most promising ones that we could actually develop, but those are additional rare indications where the PI3-kinase Delta pathway is involved“